It should also be noted that MDM2 inhibition guided by wild-type TP53 is not a clinically validated treatment strategy for patients with CRC, and the rationale for this analysis was based on previously published pre-clinical data [54]. This evidence concerns the gene MDM2 and colorectal carcinoma.